Zyprexa

Worldwide, Other products fared better.

Sales of osteoporosis medication Forteo increased 59 percent to $118 million, erectile dysfunction drug Cialis increased 38 percent and four diabetes drugs climbed 11 percent to a combined $750 million.

"Lilly is determined to be a leader in diabetes care," said Jim Ward, Lilly's executive director of investor relations.

The company is bulking up its marketing and manufacturing for the insulin medication Humalog.

Excluding certain charges in 2004 and 2005, as well as stock-option expensing in 2004, Lilly's earnings for the latest quarter would have risen to 80 cents per share, compared with 69 cents per share in the prior year.

Analysts polled by Thomson Financial expected earnings of 78 cents per share on $3.9 billion in sales.

For the full year, the company earned $1.98 billion, or $1.81 per share, versus $1.81 billion, or $1.66 a share, a year ago.

Sales rose to $14.65 billion from $13.86 billion.

Eli Lilly said it expects 2006 earnings of 73 cents to 75 cents per share for the first quarter and $3.10 to $3.20 per share for the year, with full-year sales up 7 percent to 9 percent.

Continued 1.   2.   NEXT» Print This StoryPrint This Story E-mail...

Sales of Strattera, Lilly's treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase risk of suicidal thoughts among children and adolescents.

Sales of Lilly's diabetes products rose 11 percent to $750 million, helped by the introduction of a new drug called Byetta and higher prices for older treatments.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.

Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Cialis, the anti-impotence pill sold in partnership with ICOS Corp.

(ICOS.O: Quote, Profile, Research), rose 38 percent to $211 million.

Sales of Pfizer Inc.'s (PFE.N: Quote, Profile, Research) rival Viagra fell in the quarter, hurt by competition from Lilly's longer-acting product.

Lilly reaffirmed its 2006 earnings forecast of $3.10 to $3.20 per share, first delivered last month and excluding special items.

It is in line with the average estimate of $3.13 among analysts polled by Reuters Estimates.

The company forecast first-quarter earnings of 73 cents to 75 cents per share, representing growth of 7 perce...

Sales of Strattera, Lilly‘s treatment for attention deficit disorder, slipped 8 percent to $168 million, hurt by the recent placement of a prominent warning inside the packaging that it may increase risk of suicidal thoughts among children and adolescents.

Sales of Lilly‘s diabetes products rose 11 percent to $750 million, helped by the introduction of a new drug called Byetta and higher prices for older treatments.

Sales of Alimta, a new treatment for lung cancer, rose 86 percent to $136 million.

Injectable osteoporosis drug Forteo jumped 59 percent to $118 million, while sales of older treatment Evista rose 3 percent to $265 million.

Cialis, the anti-impotence pill sold in p - ), rose 38 percent to $211 million.

S - ) rival Viagra fell in the quarter, hurt by competition from Lilly‘s longer-acting product.

Lilly reaffirmed its 2006 earnings forecast of $3.10 to $3.20 per share, first delivered last month and excluding special items.

It is in line with the average estimate of $3.13 among analysts polled by Reuters Estimates.

The company forecast first-quarter earnings of 73 cents to 75 cents per share, representing growth of 7 percent to 10 percent over the 2005 period.

The forec...